BioNTech is ready to use for approval for its COVID-19 vaccine for kids youthful than 12, the corporate introduced on Friday.
“We are going to current the outcomes of our examine amongst kids aged 5 to 11 to regulators world wide within the coming weeks, and we’ll apply for authorization of our vaccine for this age group, additionally right here in Europe,” Ozlem Tureci, BioNTech’s cofounder and chief medical officer, acknowledged German weekly.
She mentioned the vaccine is identical because the one presently in use for different age teams, however its dosage shall be modified for the youthful age group.
Early findings of research performed by the German pharma agency confirmed a decrease dose of the vaccine is protected and efficient for the 5-11 age group, and the corporate has already began preparations for manufacturing.
“It seems to be good, every thing goes in accordance with plan,” cofounder Ugur Sahin mentioned.
If the European Medicines Company offers its nod, Germany can begin vaccinations for the age group as early as mid-October, the weekly reported.